CEL SCI CORP: directors' dealings · United States · SEC (Form 4)

About CEL SCI CORP

CEL-SCI Corporation is a U.S.-listed biotechnology company traded on the NYSE American market under the ticker CVM, placing it squarely in the small-cap, high-risk, high-upside segment of healthcare equities. The company was founded in 1983 and has built its corporate identity around immunotherapy research, with the goal of developing treatments that harness the body’s immune system to fight cancer. CEL-SCI is headquartered in Vienna, Virginia, United States, in the Washington, D.C. metropolitan area. Unlike a diversified pharmaceutical group, CEL-SCI is best understood as a focused clinical-stage developer with a concentrated pipeline and value proposition. Its core business revolves around Multikine® (Leukocyte Interleukin, Injection), the company’s lead investigational therapy. Multikine is being developed primarily for certain head and neck cancers and is designed to be administered before standard cancer therapy, with the intent of stimulating an anti-tumor immune response at an early stage in the treatment pathway. CEL-SCI combines research, clinical development, and manufacturing capabilities, which is notable for a company of its size and supports its ambition to advance a complex biologic through late-stage development. From a competitive standpoint, CEL-SCI occupies a niche position rather than a commercial leadership role. It is not yet a marketed-product company; instead, it is a development-stage biotechnology name whose investment case depends on clinical data, regulatory progress, funding access, and potential partnership interest. That creates a classic biotech profile: meaningful upside if the program succeeds, but substantial binary risk, including the need for additional financing and the possibility of shareholder dilution. CEL-SCI has explicitly noted that it may need further capital or a partnering arrangement to bring Multikine to market. Recent developments remain centered on Multikine and its regulatory path. In 2025 and early 2026, the company highlighted preparations for a 212-patient confirmatory registration study in a target population of advanced head and neck cancer patients, with enrollment expected to begin in spring 2026. CEL-SCI also disclosed international regulatory activity, including a Breakthrough Medicine Designation filing in Saudi Arabia through a local pharmaceutical partner, Dallah Pharma. These updates suggest a company still in the pre-commercial stage but actively working to de-risk its lead asset and broaden its strategic optionality. For investors in French-speaking markets, CVM is best viewed as a speculative biotechnology story rather than a conventional operating company. Its valuation is largely tied to one drug candidate, one therapeutic area, and a sequence of clinical and regulatory milestones. That concentration can be powerful if execution is successful, but it also means the stock remains highly sensitive to trial outcomes, financing conditions, and management’s ability to convert scientific promise into a commercial asset.